Celine-Lea Halioua-Haubold, Jasleen K. Jolly, James Smith, Rafael Pinedo‐Villanueva, David Brindley, Robert E. MacLaren,
... relationships: Served as an advisor or consultant for Nightstar Therapeutics plc; Spark Therapeutics, Inc. Served as a ... or a member of a speakers bureau for Nightstar Therapeutics plc. Received grants for clinical research from Nightstar Therapeutics plc. CLHH, JKJ, JAS, RPV, and DAB ...
Tópico(s): Retinal Diseases and Treatments
2019 - Springer Nature | Eye
Byron L. Lam, Janet L. Davis, Ninel Z. Gregori,
... of the BCVA gain up to 12 months (Nightstar Topline Results). There was no difference detected in ... Clinical trials using the same AAV2-REP1 vector [Nightstar/Biogen timrepigene emparvovec (BIIB111/AAV2-REP1)] include the ...
Tópico(s): Retinopathy of Prematurity Studies
2021 - Lippincott Williams & Wilkins | International Ophthalmology Clinics
... by big pharma: Bamboo Therapeutics, AveXis, Spark Therapeutics, Nightstar Therapeutics, Audentes Therapeutics, Asklepios BioPharmaceutical, Juno Therapeutics and ...
Tópico(s): Biotechnology and Related Fields
2022 - Nature Portfolio | Nature Biotechnology
Thomas M. W. Buckley, Jasleen K. Jolly, Moreno Menghini, Laura J. Taylor, Anika Nanda, Robert E. MacLaren,
... subsequently enrolled into a clinical trial sponsored by Nightstar Therapeutics (NCT03116113). The views expressed are those of ...
Tópico(s): Retinal and Optic Conditions
2020 - Wiley | Clinical and Experimental Ophthalmology
Joan W. Miller, Luk H. Vandenberghe,
... biopharmaceutical companies in the gene therapy space, including Nightstar Therapeutics. Lonza, Solid, and Selecta Biosciences sponsored research ...
Tópico(s): Retinal Diseases and Treatments
2018 - Elsevier BV | Molecular Therapy
Keith Erickson, D. Gates, S. P. Gerhardt, J. Lawson, R. Mozulay, P. Sichta, G. Tchilinguirian,
... operating system and drivers (RedHawk), and RT tools (NightStar). Strong vendor support coupled with an extensive RT ...
Tópico(s): Particle accelerators and beam dynamics
2014 - Elsevier BV | Fusion Engineering and Design
Jasmina Cehajic‐Kapetanovic, Marco P. Bellini, Laura J. Taylor, Imran H. Yusuf, Taha Soomro, Lyndon da Cruz, Robert E. MacLaren,
... 12 vector particles per ml) was supplied by Nightstar Therapeutics (London, UK), now part of Biogen Inc. ( ...
Tópico(s): Retinopathy of Prematurity Studies
2023 - NIHR Journals Library | Efficacy and Mechanism Evaluation
Muneeswar Gupta Nittala, Akihito Uji, Swetha Bindu Velaga, Amir H Hariri, Joel Naor, David G. Birch, Rand Spencer, Theodore Leng, Alexandra Capela, Ann Tsukamoto, Michel Ip, Srinivas R. Sadda,
... and Roche. Dr. Birch receives research support from Nightstar, Allergan, AGTC, 4D Molecular Therapeutics, and ProQR Therapeutics. He has served as a consultant for Nightstar, AGTC, Nacuity Pharmaceuticals, Editas Medicine, Acucela, Foundation Fighting ...
Tópico(s): Retinal and Optic Conditions
2019 - RELX Group (Netherlands) | SSRN Electronic Journal
... company since 2012. Biogen acquired one of them, Nightstar, last year for $877 million.
Tópico(s): Biomedical Ethics and Regulation
2020 - American Chemical Society | C&EN Global Enterprise
Biogen says it will acquire UK-based Nightstar Therapeutics for $800 million, a 68% premium over the firm's stock market value of about $500 million on March 1, before the ...
Tópico(s): Biomedical and Engineering Education
2019 - American Chemical Society | C&EN Global Enterprise
... far in gene therapy this year, Biogen bought Nightstar Therapeutics, Roche acquired Spark Therapeutics, and Sarepta Therapeutics ...
2019 - American Chemical Society | C&EN Global Enterprise
... reeds in light winda tall boat alone at nightstars hand over the barren landthe moon rises out ...
Tópico(s): Chinese history and philosophy
2010 - Johns Hopkins University Press | Spiritus